If it works, it will be slightly disruptive...I mean, I do not see as a cure, but it could help a lot!
A Phase I/II clinical trial is underway to evaluate a hypoxia-modifying agent, IMGS-101, in combination with checkpoint inhibitors for advanced cancers. The trial targets metastatic castration-resistant prostate cancer, pancreatic cancer, and HPV-negative squamous cell carcinoma of the head and neck.
The trial represents a promising strategy to overcome hypoxia-induced immunosuppression.
Hypoxia is a major barrier to immunotherapy, as it restricts T-cell infiltration and diminishes immune responses. By reversing hypoxia, IMGS-101 may enhance the efficacy of checkpoint inhibitors.
Success could redefine the therapeutic landscape and offer new hope for patients with limited treatment options.
Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy
